1-(4-(Benzyloxy)-3-nitrophenyl)-2-bromoethanone, can be used as an intermediate in the synthesis of Arformoterol Tartrate (A767505), which is a derivative of Arformoterol, a long acting beta-adrenoceptor agonist drug indicated for the treatment of chronic obstructive pulmonary disease (COPD).
- Product Description
- Packaging & Delivery
- Shipping & Payment FAQ
Synonyms:2-Bromo-1-[3-nitro-4-(phenylmethoxy)phenyl]Ethanone; 1-(Benzyloxy)-2-nitro-4-(2-bromoacetyl)benzene; 2-Bromo-1-(3-nitro-4-benzyloxyphenyl)ethanone; 2-Bromo-4′-Benzyloxy-3′-nitroacetophenone; 4′-(Benzyloxy)-2-bromo-3′-nitroacetophenone
CAS No: 43229-01-2
Molecular formula: C15H12BrNO4
Molecular weight: 350.16 g/mol
Appearance: Off-White to Light Yellow Solid
Melting point: 135-137 °C(Solv: ethanol (64-17-5))
InChi Key: PBAAKBQGBSUCTG-UHFFFAOYSA-N
Grade Standard: Pharmaceutical-grade
Brand name: Ikigai ™
Standard: USP, Ph. Eur., JP Etc
Shipping & Storage Information
Storage: -20°C Freezer, Under inert atmosphere
Stability (shelf life): N/A
EPA CPDat Chemical and Product Categories
|Category||Category Description||Categorization Type|
|Drug||Drug product, or related to the manufacturing of drugs; modified by veterinary, animal, or pet if indicated by source||CPCat Cassette|
General Manufacturing Information
|GHS Hazard Statements||Aggregated GHS information provided by 47 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
H302 (97.87%): Harmful if swallowed [Warning Acute toxicity, oral]
H351 (95.74%): Suspected of causing cancer [Warning Carcinogenicity]
H360 (95.74%): May damage fertility or the unborn child [Danger Reproductive toxicity]
H362 (95.74%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
|Precautionary Statement Codes||P201, P202, P260, P263, P264, P270, P281, P301+P312, P308+P313, P330, P405, and P501|
Accidental Release Measures
SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state-licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.
Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any quantity of the following substances, including its salts, esters, and ethers.
Non-Human Toxicity Values
LD50 Rat (male) oral between 500 and 1000 mg/kg BW
LD50 Rat (female) oral >500 mg/kg BW
LD50 Rat (male and female) dermal >2000 mg/kg BW
Environmental Fate/Exposure Summary
Androstenedione’s production and administration as a drug to treat symptoms due to male andropause, dietary supplement, and athletic performance-enhancing drug may result in its release to the environment through various waste streams. Androstenedione is a naturally occurring androgen produced by the adrenal gland and converted to testosterone or estrone. It is produced naturally in humans during the production of testosterone and estrogen. It can be formed in soils via the metabolism of testosterone and estradiol occurring in poultry and livestock manures used as agricultural fertilizers. If released to air an extrapolated vapor pressure of 7.35X10-9 mm Hg at 20 °C indicates androstenedione will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase androstenedione will be degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals and with ozone; the half-lives for these reactions in the air are estimated to be 3.5 hours and 1 day respectively. Particulate-phase androstenedione will be removed from the atmosphere by wet and dry deposition. Androstenedione absorbs light at wavelengths >290 nm, and therefore, may be susceptible to direct photolysis. If released to soil, androstenedione is expected to have no mobility based upon a Koc of 6170. Volatilization from moist soil surfaces is not expected to be an important fate process based upon an estimated Henry’s Law constant of 3.7X10-8 atm-cu m/mole. Androstenedione is not expected to volatilize from dry soil surfaces based upon its vapor pressure. Results of soil column studies using various soils and sands found that half-life of androstenedione ranged from 1.7 to 77 hours. If released into water, androstenedione is expected to adsorb to suspended solids and sediment based upon the Koc. Using OECD Guideline 301B (CO2 Evolution Test), androstenedione reached 79-95% degradation over a 28-day incubation period which classified the compound as readily biodegradable. Volatilization from water surfaces is not expected to be an important fate process based upon this compound’s estimated Henry’s Law constant. An estimated BCF of 30 suggests the potential for bioconcentration in aquatic organisms is low to moderate. Hydrolysis is not expected to be an important environmental fate process since this compound lacks functional groups that hydrolyze under environmental conditions. Androstenedione in aqueous solutions underwent direct photolysis half-lives ranging from 3.7 to 10.8 hours in direct sunlight. Occupational exposure to androstenedione may occur through dermal contact with this compound at workplaces where androstenedione is produced or used.
2000 Metric Ton/Metric Tons per Month
Packaging & Delivery
- by Air Freight & Cargo
- by Sea Freight & Cargo (Container shipping)
- by Rail Freight (train)
- by Road Freight
- by Intermodal freight transport
Question 1: How to start orders for API materials?
Answer: Pro-forma invoice will be sent first after confirmation of the order, enclosed our payment information. Payment by T/T, Paypal, and others. All courier tracking numbers are provided upon shipping.
Question 2: What’s your MOQ?
Answer: The MOQ for this API is 1kg.
Question 3: How to guarantee safe shipment?
Answer: We have shipping insurance. Our experienced team will do the customs documents, generally, it will have no trouble. And we will reship or refund for you if it is seized by our mistake.
Question 4: How about delivery lead-time?
Answer: Shipping lead time: About 2-5 days after payment confirmed. (Chinese holiday not included), We have long-term relations with shipping agents in main Chinese ports. Full service can be offered, including photos of every shipment, marks, and procedure of loading. General times are gor 1KG-100KG, Within 5-7 days by DHL, UPS, TNT, FEDEX, EMS Over 100KG. within 5-8days by air, 20-40days by sea. More information.
Question 5: Is there a discount?
Answer: Different quantity has a different discount. Please feel free to contact us.
Question 6: How to contact us?
Question 7:How do you treat quality complaints?
Answer: Our quality control will reduce the quality problem to near zero. If there is a real quality problem caused by us, we will send you free goods for replacement or refund your loss. We are competitive in API exporting, Pharmaceutical excipients, food supplements, dyestuff, veterinary API. Our team has 20 years of experience in this business. Good team for quality control, shipping, and documents.
Question 8: Payment methods you accept?
U.S. funds preferably.
The negative impact of the production of pharmaceutical products on the natural environment is well known. However, this remains largely unregulated, meaning the extremely toxic impact it has on both animals and humans continues with no clear end in sight. As Ikigai Corporation Company Innovator, we are committed to expanding and improving our efforts to safeguard the environment. We accordingly established our environmental management system
Quality Management, Environmental Management and Occupational Safety Policy
Ikigai Corporation Company is engaged in the production and distribution of pharmaceutical substances and other chemical specialties. As a chemical and pharmaceutical manufacturer, the Company is aware of the impacts of its activities on the product quality, on the environment and the health of its employees, and undertakes to control them, with the aim of constant improvement.
As standards for the implementation and maintenance of the Integrated Management System, the Company has chosen international standards ISO 9001 in the area of quality management (hereinafter called QMS), ISO 14001 for the management of environmental protection (hereinafter called EMS) and specification OHSAS 18000 for ensuring the occupational safety and health protection (hereinafter called SMS). The Integrated Management System applies to all fields of the Company’s activities.
Within this Policy, Ikigai Corporation Company undertakes to:
Constantly improve all of its activities
Executive commitment to continually improve energy efficiency across the entire corporation, including clear processes and tracking systems to identify opportunities
An empowered corporate energy director and energy team supported by sufficient human and financial resources
A corporate energy policy that is accounted for at the top levels of the corporation
Aggressive, numeric energy goals that stretch performance targets to draw out creative innovations for meeting them
Measurement and tracking of energy performance for all energy use, corporationwide, including benchmarking facility performance nationally and globally with similar companies, and a review system with accountability at all levels
Communication of the value of energy savings, importance of improving use of energy and executive commitment by consistently recognizing accomplishments.
Abide by the relevant legislation and other regulations which apply to the Company or which the Company has committed to observe; especially the requirements arisen from the Act on Pharmaceuticals, the Decree on Good Manufacturing Practice and other guidelines and directives and other requirements related to the occupational safety and the environmental protection.
Constantly educate and train its employees and strongly encourage them to improve the production quality, protect the environment and observe the occupational safety principles; to design the training so as to motivate the employees performing their jobs to prevent or reduce negative impacts of all activities on the environment.
Develop communication and cooperation with the public administration bodies, professional public and other parties concerned with the environmental protection issues. Ikigai Corporation Company is interested in holding open dialogue with the employees and the public, in informing both internal and external stakeholders of the impacts of all the Company’s activities on the environment and in responding to justified suggestions and concerns.
The executive management expects that all the Company employees will accept an opinion that observing the above mentioned principles and objectives is one of the most fundamental duties of every employee in the Company.